project id: TCGA-PRAD; case submitter id: TCGA-J9-A8CN; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.93; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.34; rna integrity number: 7.8; age at index: 53; days to birth: -19662; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1958; age at diagnosis: 19662; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1237.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 971; initial weight: 100.0; sample id: f9160e70-27f0-4c8c-a667-b24195ad659c; sample submitter id: TCGA-J9-A8CN-01A; portion id: 8ea4c9cd-6124-4afe-942e-f21ac046d87a; portion submitter id: TCGA-J9-A8CN-01A-11; slide id: 3f5ceb9c-72a3-470f-a7b4-ac54a32a3f25; slide submitter id: TCGA-J9-A8CN-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 15.0; percent tumor cells: 85.0; percent tumor nuclei: 90.0; section location: TOP;